Key Treatment Data in Urothelial Carcinoma

EP: 1.Patient Profile 1: A 72-Year-Old With Metastatic Urothelial Carcinoma

EP: 2.Overview of Urothelial Carcinoma

Now Viewing

EP: 3.Key Treatment Data in Urothelial Carcinoma

EP: 4.Urothelial Carcinoma: Adverse Events From Sacituzumab Govitecan

EP: 5.Patient Profile 2: A 76-Year-Old With Locally Advanced, Resectable Urothelial Carcinoma

EP: 6.EV-103: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

EP: 7.Urothelial Carcinoma: Safety Profile of Enfortumab Vedotin and Pembrolizumab

EP: 8.Clinical Insights on Evolving Treatment Landscape in Urothelial Carcinoma

Case 1: A 72-Year-Old Man with Metastatic Urothelial Carcinoma

Initial Clinical Presentation: 

• A 72-year-old man presented to the clinic with complaints of dizziness and hematuria.
• PMH: Obesity (BMI) and poorly controlled type 2 diabetes (blood sugar, 200 mg/dL)
• SH: Patient does not smoke and occasionally drinks, in social settings.

Initial Clinical Workup: 

• CT of chest, abdomen, and pelvis revealed a 3.5-cm mass in the bladder and multiple liver metastases
• ECOG PS 1
• eGFR > 60 mL/min (cisplatin-eligible kidney function)
• Biopsy/pathology confirmed stage IV metastatic urothelial carcinoma
• Molecular testing: FGFR2/3 mutation and fusionnegative

Initial Treatment and Disease Progression:

• Patient received platinum-based chemotherapy with cisplatin.
  • Experiences platinum-based peripheral neuropathy (paresthesia) that interrupted the patient’s quality of life.
    • Neuropathy was low grade AE (Grade 1)which improved to Grade 0 with supportive care.
  • Partial response after 4 cycles of cisplatin; ECOG PS 1
  • Imaging showed no growth of existing lesions or new lesions after 4 cycles ​
• Followed with IO maintenance with avelumab 800 mg IV infusion over 60 minutes every two weeks.
  • Following 9 cycles, patient achieved partial response in the lung and bladder.
  • Liver function tests, CrCl, and other labs were within normal limits
  • No infusion reactions
  • 5 months later, disease progression is confirmed
• Patient was initiated on sacituzumab govitecan 10 mg/kg on Days 1 and 28 for 21-day continuous treatment cycle.
  • Patient experiences grade 3 neutropenia at the time of schedule treatment.
  • Delay dosing by 2 weeks until recovery to less than grade 1. Managed with 25% dose reduction and administration of G-CSF.